Since October 2018 the business unit Pharmaceuticals of Seibersdorf Labor GmbH is the European manufacturing partner of the Australian biopharma company Telix for the production of the diagnostic and therapeutic radiopharmaceutical TLX101, intended for the treatment of glioblastoma, an aggressive form of brain cancer. This cooperation ensures the supply with TLX101 in Europe.

>> see full text of English press release